Human induced pluripotent stem cell line banking for the production of rare blood type erythrocytes
Authors:
Open Access
- 12 June 2020
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-12
Abstract
Background: The in vitro production of mature human red blood cells (RBCs) from induced pluripotent stem cells (iPSCs) has been the focus of research to meet the high demand for blood transfusions. However, limitations like high costs and technological requirements restrict the use of RBCs produced by iPSC differentiation to specific circumstances, such as for patients with rare blood types or alloimmunized patients. In this study, we developed a detailed protocol for the generation of iPSC lines derived from peripheral blood of donors with O D-positive blood and rare blood types (D–and Jr(a-)) and subsequent erythroid differentiation. Methods: Mononuclear cells separated from the peripheral blood of O D-positive and rare blood type donors were cultured to produce and expand erythroid progenitors and reprogrammed into iPSCs. A 31-day serum-free, xeno-free erythroid differentiation protocol was used to generate reticulocytes. The stability of iPSC lines was confirmed with chromosomal analysis and RT-PCR. Morphology and cell counts were determined by microscopy observations and flow cytometry. Results: Cells from all donors were successfully used to generate iPSC lines, which were differentiated into erythroid precursors without any apparent chromosomal mutations. This differentiation protocol resulted in moderate erythrocyte yield per iPSC. Conclusions: It has previously only been hypothesized that erythroid differentiation from iPSCs could be used to produce RBCs for transfusion to patients with rare blood types or who have been alloimmunized. Our results demonstrate the feasibility of producing autologous iPSC-differentiated RBCs for clinical transfusions in patients without alternative options.Keywords
Funding Information
- Severance Hospital Research fund for Clinical excellence (C-2019-0034)
This publication has 56 references indexed in Scilit:
- Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expressionNature Protocols, 2012
- Banking of Pluripotent Adult Stem Cells as an Unlimited Source for Red Blood Cell Production: Potential Applications for Alloimmunized Patients and Rare Blood ChallengesTransfusion Medicine Reviews, 2011
- Generation of Red Blood Cells from Human Induced Pluripotent Stem CellsStem Cells and Development, 2011
- Implications of demographics on future blood supply: a population‐based cross‐sectional studyTransfusion, 2010
- Stroma‐free mass production of clinical‐grade red blood cells (RBCs) by using poloxamer 188 as an RBC survival enhancerTransfusion, 2009
- In vitro clinical‐grade generation of red blood cells from human umbilical cord blood CD34+ cellsTransfusion, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation culturesBlood, 2006
- Ex vivo generation of fully mature human red blood cells from hematopoietic stem cellsNature Biotechnology, 2005
- An Example of Anti‐Jra Causing Hemolytic Disease of the Newborn and Frequency of Jra Antigen in the Japanese PopulationVox Sanguinis, 1978